BR112015030385A8 - composto, composto para uso e composição farmacêutica - Google Patents

composto, composto para uso e composição farmacêutica Download PDF

Info

Publication number
BR112015030385A8
BR112015030385A8 BR112015030385A BR112015030385A BR112015030385A8 BR 112015030385 A8 BR112015030385 A8 BR 112015030385A8 BR 112015030385 A BR112015030385 A BR 112015030385A BR 112015030385 A BR112015030385 A BR 112015030385A BR 112015030385 A8 BR112015030385 A8 BR 112015030385A8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
methods
pi3k
ameliorating
Prior art date
Application number
BR112015030385A
Other languages
English (en)
Other versions
BR112015030385B1 (pt
BR112015030385A2 (pt
Inventor
Babu Govindarajulu
K Bhavar Prashant
Viswanadha Srikant
K V S Vakkalanka Swaroop
Original Assignee
Rhizen Pharmaceuticals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals S A filed Critical Rhizen Pharmaceuticals S A
Publication of BR112015030385A2 publication Critical patent/BR112015030385A2/pt
Publication of BR112015030385A8 publication Critical patent/BR112015030385A8/pt
Publication of BR112015030385B1 publication Critical patent/BR112015030385B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Abstract

a presente invenção refere-se a moduladores de proteína quinase delta (d) e gama (¿) pi3k duplos, métodos de preparação dos mesmos, composições farmacêuticas que contêm os mesmos e métodos de tratamento, prevenção e/ou melhora de doenças ou distúrbios mediados por pi3k quinase com os mesmos.
BR112015030385-4A 2013-06-07 2014-06-04 Composto, composto para uso e composição farmacêutica BR112015030385B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN2501CH2013 2013-06-07
IN2501/CHE/2013 2013-06-07
IN5567CH2013 2013-12-03
IN5567/CHE/2013 2013-12-03
PCT/IB2014/061954 WO2014195888A1 (en) 2013-06-07 2014-06-04 Dual selective pi3 delta and gamma kinase inhibitors

Publications (3)

Publication Number Publication Date
BR112015030385A2 BR112015030385A2 (pt) 2017-07-25
BR112015030385A8 true BR112015030385A8 (pt) 2019-12-24
BR112015030385B1 BR112015030385B1 (pt) 2020-08-18

Family

ID=50980341

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015030385-4A BR112015030385B1 (pt) 2013-06-07 2014-06-04 Composto, composto para uso e composição farmacêutica

Country Status (31)

Country Link
US (3) US9790224B2 (pt)
EP (1) EP3004106B1 (pt)
JP (1) JP6499165B2 (pt)
KR (1) KR102292853B1 (pt)
CN (1) CN105358560B (pt)
AP (1) AP2015008888A0 (pt)
AR (1) AR096543A1 (pt)
AU (1) AU2014276476B2 (pt)
BR (1) BR112015030385B1 (pt)
CA (1) CA2913226C (pt)
CL (1) CL2015003562A1 (pt)
CY (1) CY1119615T1 (pt)
DK (1) DK3004106T3 (pt)
EA (1) EA029017B1 (pt)
ES (1) ES2648094T3 (pt)
HK (1) HK1217949A1 (pt)
HR (1) HRP20171795T1 (pt)
HU (1) HUE035237T2 (pt)
IL (1) IL242761B (pt)
LT (1) LT3004106T (pt)
MX (1) MX366449B (pt)
NO (1) NO3004106T3 (pt)
PH (1) PH12015502698B1 (pt)
PL (1) PL3004106T3 (pt)
PT (1) PT3004106T (pt)
RS (1) RS56606B1 (pt)
SG (1) SG11201509992RA (pt)
SI (1) SI3004106T1 (pt)
TW (1) TWI615144B (pt)
WO (1) WO2014195888A1 (pt)
ZA (1) ZA201508708B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2800913C (en) 2010-06-03 2019-07-23 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
BR112015001690A2 (pt) 2012-07-24 2017-11-07 Pharmacyclics Inc mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk)
US10351626B2 (en) 2013-03-14 2019-07-16 The Scripps Research Institute Targeting agent antibody conjugates and uses thereof
CA2913226C (en) * 2013-06-07 2023-01-03 Rhizen Pharmaceuticals Sa Dual selective pi3 delta and gamma kinase inhibitors
EA201592157A1 (ru) 2013-06-07 2016-05-31 Дзе Калифорния Инститъют Фор Биомедикал Рисёрч Низкомолекулярные ингибиторы фиброза
WO2016094570A1 (en) 2014-12-10 2016-06-16 The California Institute For Biomedical Research Small molecule inhibitors of fibrosis
CA2970043A1 (en) * 2014-12-23 2016-06-30 Pharmacyclics Llc Btk inhibitor combinations and dosing regimen
JP2021505571A (ja) * 2017-12-06 2021-02-18 ルヒゼン ファーマスティカルズ エスエー 末梢ｔ細胞リンパ腫および皮膚ｔ細胞リンパ腫を治療するための組成物および方法
EP4149629A1 (en) 2020-05-14 2023-03-22 Rhizen Pharmaceuticals AG Purine derivatives as sik-3 inhibitors
WO2023125419A1 (zh) * 2021-12-31 2023-07-06 同润生物医药(上海)有限公司 一种己二酸盐结晶及其制备方法
TW202328132A (zh) * 2021-12-31 2023-07-16 大陸商同潤生物醫藥(上海)有限公司 ＰＩ３Ｋδ／γ雙重抑制劑化合物的半富馬酸鹽結晶及其製備方法
WO2023125418A1 (zh) * 2021-12-31 2023-07-06 同润生物医药(上海)有限公司 一种苯磺酸盐结晶及其制备方法
WO2023130334A1 (zh) * 2022-01-07 2023-07-13 同润生物医药(上海)有限公司 一种色烯-4-酮化合物及其中间体的制备方法
WO2023209634A1 (en) 2022-04-29 2023-11-02 Rhizen Pharmaceuticals Ag A dual selective pi3k delta and gamma inhibitors and/or a salt-inducible kinase 3 inhibitor for treating solid tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010316780B2 (en) * 2009-11-05 2015-07-16 Rhizen Pharmaceuticals Sa Novel benzopyran kinase modulators
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
MY168757A (en) * 2011-05-04 2018-12-04 Rhizen Pharmaceuticals S A Novel compounds as modulators of protein kinases
WO2013164801A1 (en) 2012-05-04 2013-11-07 Rhizen Pharmaceuticals Sa Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals
CA2913226C (en) * 2013-06-07 2023-01-03 Rhizen Pharmaceuticals Sa Dual selective pi3 delta and gamma kinase inhibitors
JP2021505571A (ja) * 2017-12-06 2021-02-18 ルヒゼン ファーマスティカルズ エスエー 末梢ｔ細胞リンパ腫および皮膚ｔ細胞リンパ腫を治療するための組成物および方法

Also Published As

Publication number Publication date
TWI615144B (zh) 2018-02-21
NO3004106T3 (pt) 2018-01-27
HRP20171795T1 (hr) 2018-01-26
CA2913226A1 (en) 2014-12-11
AP2015008888A0 (en) 2015-11-30
CA2913226C (en) 2023-01-03
EA029017B1 (ru) 2018-01-31
US10851107B2 (en) 2020-12-01
SI3004106T1 (en) 2018-03-30
BR112015030385B1 (pt) 2020-08-18
PH12015502698A1 (en) 2016-03-14
JP6499165B2 (ja) 2019-04-10
KR102292853B1 (ko) 2021-08-24
CN105358560A (zh) 2016-02-24
LT3004106T (lt) 2018-02-26
CL2015003562A1 (es) 2016-08-05
PH12015502698B1 (en) 2016-03-14
IL242761B (en) 2018-11-29
AU2014276476A1 (en) 2015-12-10
KR20160017047A (ko) 2016-02-15
ZA201508708B (en) 2017-02-22
US20140364447A1 (en) 2014-12-11
CY1119615T1 (el) 2018-04-04
PL3004106T3 (pl) 2018-01-31
MX366449B (es) 2019-07-09
AR096543A1 (es) 2016-01-13
EA201592113A1 (ru) 2016-05-31
AU2014276476B2 (en) 2018-05-10
HK1217949A1 (zh) 2017-01-27
NZ714465A (en) 2021-03-26
US9790224B2 (en) 2017-10-17
EP3004106B1 (en) 2017-08-30
RS56606B1 (sr) 2018-02-28
CN105358560B (zh) 2017-03-08
SG11201509992RA (en) 2016-01-28
US11466006B2 (en) 2022-10-11
US20170334914A1 (en) 2017-11-23
EP3004106A1 (en) 2016-04-13
HUE035237T2 (hu) 2018-05-02
BR112015030385A2 (pt) 2017-07-25
ES2648094T3 (es) 2017-12-28
TW201517908A (zh) 2015-05-16
US20210032248A1 (en) 2021-02-04
DK3004106T3 (en) 2017-12-04
JP2016520644A (ja) 2016-07-14
MX2015016741A (es) 2016-11-14
WO2014195888A1 (en) 2014-12-11
PT3004106T (pt) 2017-11-27

Similar Documents

Publication Publication Date Title
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
BR112018008918A8 (pt) compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
CR20170478A (es) Compuestos novedosos
BR112015029969A2 (pt) tratamento de câncer usando moduladores de isoformas quinase pi3
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
BR112015019794A8 (pt) Composto, composição farmacêutica, agonista do receptor de esfingosina-1-fosfato, e, uso de um composto
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112015023760A2 (pt) compostos e composições terapêuticas
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
BR112014030655A8 (pt) Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende
BR112017008714A2 (pt) inibidores de bromodomínio
BR112017002214A2 (pt) composto de fórmula (i), composição farmacêutica e usos de um composto
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112017003433A2 (pt) inibidores espirocíclicos de catepsina c
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/06/2014, OBSERVADAS AS CONDICOES LEGAIS.